Session » Systemic Sclerosis & Related Disorders – Basic Science Poster

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1071

A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1065

Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1054

Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis

9:00AM-11:00AM: Abstract Number: 1059

BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo

9:00AM-11:00AM: Abstract Number: 1072

CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 1064

CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy

9:00AM-11:00AM: Abstract Number: 1069

CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1068

Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures

9:00AM-11:00AM: Abstract Number: 1048

Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1041

Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses

9:00AM-11:00AM: Abstract Number: 1047

CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage

9:00AM-11:00AM: Abstract Number: 1070

Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1057

Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma

9:00AM-11:00AM: Abstract Number: 1066

Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1063

Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1074

Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells

9:00AM-11:00AM: Abstract Number: 1050

Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1051

Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1073

Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1067

Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis

9:00AM-11:00AM: Abstract Number: 1049

Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 1058

Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis

9:00AM-11:00AM: Abstract Number: 1062

Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1045

Myocardial Involvement in SSc: Key Role of Lin-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System

9:00AM-11:00AM: Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo

9:00AM-11:00AM: Abstract Number: 1061

PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis

9:00AM-11:00AM: Abstract Number: 1056

Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway

9:00AM-11:00AM: Abstract Number: 1040

Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity

9:00AM-11:00AM: Abstract Number: 1055

Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts

9:00AM-11:00AM: Abstract Number: 1044

TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?

9:00AM-11:00AM: Abstract Number: 1060

The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients

9:00AM-11:00AM: Abstract Number: 1046

The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1043

The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 1052

The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 1042

Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].